Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission
August 04, 2025
Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.
Author: Russ Conroy
Fact checked by: Roman Fabbricatore
UPDATES AND NEWS
Five Leading Cancer Centers Unite to Target CD123 and Eradicate Hidden Leukemia Cells
More Than a Patient: How Holly Folgia Turned Her Cancer Journey Into Impact
One Surgery Could Prevent Most Ovarian Cancers, Surgeons Say | The ASCO Post
Conquering Cancer: Innovations Closing Gaps and Improving Outcomes | Milken Institute
BE PART OF THE MISSION
Stay Informed, Make an Impact
Subscribe
Be the first to hear about cutting-edge research, pioneering projects, and the latest advancements in Break Through Cancer science. Sign up to stay informed.
Give
Your contribution fuels groundbreaking research in some of the most challenging cancers. Every gift accelerates progress. For more information please contact Michaela Forand at MF@breakthroughcancer.org or 1-800-757-9881 ext 2.